Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04886739 · ClinicalTrials.gov registry record · Phase 2
CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea
A Phase 2 study, sponsored by CAGE Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
NCT04886739: Completed Phase 2 study, sponsored by CAGE Bio.
NCT04886739 is a Phase 2 study that has completed, run by CAGE Bio. The registered enrollment target is 78 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04886739, a Phase 2 study, has completed, sponsored by CAGE Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind, vehicle-controlled, parallel design study evaluating the efficacy and safety of CGB-400 Topical Gel for the treatment of inflammatory lesions of rosacea. The study consists of a 12-week double-blind treatment period with clinic visits at Baseline (Day 0), and Weeks 2, 4, 8, and 12. Approximately 80 subjects will be enrolled and randomized at a 1:1 ratio to treatment with either CGB-400 Topical Gel (40%) BID or Vehicle Gel BID.
Primary Outcome
Numerical count of inflammatory lesions (pustules and papules)
Interventions
- DRUG Vehicle Gel
- DRUG CGB-400
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2021-05-07 |
| Est. Completion | 2021-12-22 |
| Phase | Phase 2 |
What the finished NCT04886739 record still lists
NCT04886739 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% lower).
The record links to 0 conditions, and to 2 interventions - of which Vehicle Gel is the first listed.
NCT04886739 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04886739 about?
NCT04886739 is a clinical study titled "CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea". This is a multicenter, randomized, double-blind, vehicle-controlled, parallel design study evaluating the efficacy and safety of CGB-400 Topical Gel for the treatment of inflammatory lesions of rosacea. The study consists of a 12-week double-blind treatment period with clinic visits at Baseline (Day...
What is the current status of trial NCT04886739?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2021-05-07. Estimated completion is 2021-12-22.
What interventions are being tested in trial NCT04886739?
The interventions under investigation include: Vehicle Gel (DRUG), CGB-400 (DRUG).
Who is sponsoring clinical trial NCT04886739?
This trial is sponsored by CAGE Bio, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04886739's enrollment target sits among peer trials
78 884th of 2000 higher than 1,110 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI